Comparative Pharmacology
Head-to-head clinical analysis: METRETON versus METROLOTION.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRETON versus METROLOTION.
METRETON vs METROLOTION
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine and mast cell stabilizer. Competitively inhibits histamine at H1 receptors and prevents release of histamine and other mediators from mast cells.
Metrolotion is a formulation of metronidazole, a nitroimidazole antibiotic. Its exact mechanism is not fully understood, but it is believed to involve reduction of the nitro group in anaerobic bacteria and protozoa, leading to DNA disruption and cell death. It also has anti-inflammatory and immunosuppressive properties, possibly by inhibiting neutrophil chemotaxis and reactive oxygen species.
1-2 mg/kg intramuscularly or intravenously every 6-8 hours as needed; maximum 100 mg per dose.
Topical metronidazole (Metrolotion) 1%: Apply a thin layer to affected areas once daily.
None Documented
None Documented
Terminal elimination half-life is 24-36 hours; increased in renal impairment (up to 60 hours in anuria)
Terminal elimination half-life is 18-24 hours; allows once-daily dosing.
Renal (80-90% as unchanged drug and metabolites), biliary/fecal (10-20%)
Renal: 70% as unchanged drug; biliary/fecal: 30% as metabolites.
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)